CGRP Inhibition, Autonomic Function, and Migraine

Launched by MEDICAL UNIVERSITY OF VIENNA · Nov 12, 2020

Keywords

ClinConnect Summary

This clinical trial is looking to understand how the autonomic nervous system, which controls bodily functions we don’t consciously think about (like heart rate and digestion), works in people who suffer from migraines. The researchers want to see if these functions change when a person is experiencing a migraine versus when they are not. They are also interested in whether a specific type of medication, called CGRP monoclonal antibodies, can affect these autonomic functions. While previous studies have shown that these medications can help reduce the number of migraine attacks, this trial is not focused on how often migraines occur.

To be eligible for the study, participants should be between the ages of 18 and 65 and have either chronic migraines or episodic migraines that haven’t responded to three or more standard treatments. Healthy volunteers without any history of migraines are also needed for comparison. Participants will undergo various tests to measure their autonomic functions and will receive care related to the study. It’s important to note that certain health conditions and recent surgeries may make someone ineligible to participate. If you're interested in learning more about this trial or think you might qualify, please reach out to the research team for further details.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Chronic migraine according to ICHD-3
• • Episodic migraine without aura or with aura according to ICHD-3
• • Unsuccessful treatment with 3 or more established prophylactic drugs
• • Medicine costs are covered by health insurance
• • Healthy controls must be free from any diagnosed chronic disease or acute infection requiring medication
• Exclusion Criteria:
• • Pregnancy and lactation
• • Neurosurgical interventions performed within the last 12 months
• • Coronary bypass surgery or revascularization procedures performed within the last 12 months
• • History of transient ischemic attacks (TIA), stroke, stable or unstable angina pectoris, myocardial infarction or uncontrolled hypertension
• • Known hypersensitivity to therapy with an anti-CGRP Antibodies
• • History of a disorder (other than migraine) that may affect the results of autonomic tests
• • Healthy controls must have no personal or family history of migraine